|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
In-Depth Discussion: BlueWind Implant for Overactive Bladder Treatment - A Promising Breakthrough in Urology
|
|
John Heesakkers, MBA, MD, Ph.D.
|
| John Heesakkers discusses the BlueWind system's clinical trial, an innovative implant designed to treat overactive bladder. Dr. Heesakkers provides an in-depth explanation of the device's evolution, which began in the early 2000s with transcutaneous tibial nerve stimulation.
|
|
|
|
|
|
|
|
|
|
|
|
|
Developing A Novel Neuromodulation Therapy for Treating Overactive Bladder
|
|
Anne Agur, Ph.D.
|
| Diane Newman is joined by Anne Agur to share how they collect data to develop novel models of the human saphenous nerve. These novel models of the human saphenous nerve will be used to develop neuromodulation therapy approaches, both an engineering finite element approach and for clinicians to look at electrode placement.
|
|
|
|
|
|
|
|
|
|
|
|
|
Phase 2a Trial Results: Promising Gene Therapy for Overactive Bladder - URO-902 Safety and Efficacy Evaluation
|
|
Kenneth Peters, MD
|
| Ken Peters joins Diane Newman to present the results of a Phase 2a trial evaluating the safety and efficacy of URO-902, an investigational gene therapy for overactive bladder.
|
|
|
|
|
|
|
|
|
|
|
|
| Does Percutaneous Tibial Nerve Stimulation Predict Outcome to Sacral Nerve Stimulation?
|
| Konstantinos Kapriniotis, Julie Jenks, Bogdan Toia et al.
|
| This was a retrospective review of hospital databases since 2014 to collect all patients who had percutaneous tibial nerve stimulation (PTNS) and who subsequently had a sacral nerve stimulation (SNS) trial performed in two tertiary hospitals with the aim to determine if PTNS response is a reliable indicator to subsequent SNS trials. |
|
|
|
|
|
|
|
|
|
|
| The Use of Peripheral Tibial Nerve Stimulation as an Alternative Treatment for Overactive Bladder/Incontinence
|
| Lynn M. Allmond, FNP-BC
|
| Nurse practitioner Lynn Allmond discusses peripheral tibial nerve stimulation (PTNS) as a treatment for overactive bladder and incontinence. PTNS involves indirect stimulation of the sacral nerve plexus via the tibial nerve, and while its exact mechanism is not fully understood, it is believed to influence the nerves that affect the bladder. The procedure, typically administered once a week for 12 weeks, has shown efficacy in treating overactive bladder symptoms.
|
|
|
|
|
|
| A 3D Digital Map of the Human Saphenous Nerve: A Neuroanatomical Approach to Developing A Novel Neuromodulation Therapy for Treating Overactive Bladder
|
| Michael Peng, Paul Yoo, and Anne Agur
|
| This study focused on the saphenous nerve (SAFN) and its potential for stimulating it to treat overactive bladder (OAB). Through a 3D digital map created from dissections of lower limb specimens, researchers identified the subcutaneous distribution of nerve branches and variations in their branching patterns. This data may be instrumental in developing precise neuromodulation therapies for OAB and similar conditions.
|
|
|
|
|
|
| Efficacy And Safety Of A Novel Gene Therapy (URO-902; PVAX/HSLO) In Female Patients With Overactive Bladder Syndrome And Urgency Urinary Incontinence: Results From A Phase 2a Trial
|
| Kenneth M. Peters, MD
|
| URO-902 is an intradetrusor injection investigational gene therapy for overactive bladder (OAB). It consists of a plasmid vector that expresses the α subunit of the large-conductance Ca2+-activated K+ channel in the detrusor to reduce bladder hypercontractility. This presentation reported on results from a 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation phase 2a trial assessing the safety and efficacy.
|
|
|
|
|
|
